Additionally, Prasad et al.’s (2012) research group intravenously infused 11 patients with 80 million autologous BM-MNCs (mean 0.92 × 106 CD34+ cells) within 7–30 days of stroke onset and also confirmed the safety and feasibility of this treatment protocol. This evidence concerns the gene CD34 and stroke disorder.